NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system (CNS) disorders, ...
Scientists have zeroed in on a critical weak spot behind a rare but devastating brain autoimmune disorder often known as ...
Researchers review the future of schizophrenia treatment, highlighting TAAR1 agonists, NMDA enhancers, and the gut-brain axis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results